ARDS患者巨细胞病毒再激活的临床与生物学特征:一项前瞻性队列研究
该前瞻性队列纳入151例ARDS患者,入ICU时评估巨细胞病毒再激活,随访90天。再激活率31.1%(47/151),再激活组90天死亡率38.3% vs 21.2%(HR 2.09,95%CI 1.12–3.90,P=0.018),多因素校正后仍显著(校正HR 1.97)。再激活组无呼吸机天数更少(均数差−12.48,95%CI −17.75至−7.22),ICU住院更长(均数差16.22,95%CI 8.36–24.09)。肺内再激活者死亡风险更高;蛋白组学显示BALF免疫、补体及核糖体亚基生物合成通路受抑,血浆免疫反应激活;代谢组学显示血浆色氨酸代谢及BALF嘧啶代谢上调。
要点
- ARDS患者入ICU时评估,90天内巨细胞病毒再激活率31.1%(47/151)。
- 再激活组90天死亡率38.3% vs 未再激活组21.2%,HR 2.09(95%CI 1.12–3.90),多因素校正后校正HR 1.97(95%CI 1.04–3.74)。
- 再激活组无呼吸机天数均数差−12.48(95%CI −17.75至−7.22),ICU住院均数差16.22(95%CI 8.36–24.09),均显著差于未再激活组。
- 亚组分析显示肺内再激活患者死亡风险更高。
- 再激活组BALF免疫、补体及核糖体亚基生物合成通路受抑,血浆免疫反应激活;血浆色氨酸代谢及BALF嘧啶代谢上调。
适用人群与场景
- 急性呼吸窘迫综合征(ARDS)患者,入ICU时评估巨细胞病毒再激活。
研究设计与关键结果
- 前瞻性队列研究,纳入151例ARDS患者,分析151份血浆和48份BALF样本。
- 90天随访期间巨细胞病毒再激活率31.1%(47/151)。
- 主要终点90天死亡率:再激活组38.3% vs 未再激活组21.2%,HR 2.09(95%CI 1.12–3.90,P=0.018);多因素回归校正HR 1.97(95%CI 1.04–3.74,P=0.037);时间依赖Cox回归时间校正HR 2.61(95%CI 1.38–4.94,P=0.003)。
- 再激活组无呼吸机天数均数差−12.48(95%CI −17.75至−7.22,P<0.001),ICU住院均数差16.22(95%CI 8.36–24.09,P=0.006),回归校正后仍显著。
- 亚组分析:肺内再激活患者死亡风险更高。
- 蛋白组学:再激活组BALF免疫、补体及核糖体亚基生物合成通路受抑,血浆免疫反应激活。
- 代谢组学:再激活组血浆色氨酸代谢显著上调,BALF嘧啶代谢显著上调。
- 与死亡增加相关的生物标志物:BALF中CXCL5(相关系数0.301,P=0.038)、DERPC(相关系数−0.314,P=0.030),血液中PTX3(相关系数0.291,P<0.001)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现为巨细胞病毒再激活对ARDS患者的影响提供了新见解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cytomegalovirus (CMV) can be reactivated in patients with acute respiratory distress syndrome (ARDS), a condition associated with poor prognosis. However, the biological characteristics and bio-clinical connection of CMV reactivation remain unclear. METHODS: CMV reactivation was assessed in ARDS patients upon ICU admission. Clinical characteristics and outcomes were analysed. The primary outcome was 90-day mortality. Multivariate and time-dependent Cox regression analyses were performed. Plasma and bronchoalveolar lavage fluid (BALF) samples were collected for proteomic and metabolomic analyses to explore underlying associations. RESULTS: In total, 151 ARDS patients were included; 151 plasma and 48 BALF samples were analysed. During 90-day follow-up, CMV reactivation was observed in 31.1% (47/151) of patients. Patients with CMV reactivation exhibited significantly higher mortality (38.3% vs. 21.2%; hazard ratio [HR] 2.09, 95% confidence interval [CI] 1.12–3.90, P = 0.018). This result remained significant after multivariate regression (adjusted HR 1.97, 95% CI 1.04–3.74, P = 0.037) and time-dependent Cox regression (time-adjusted HR 2.61, 95% CI 1.38–4.94, P = 0.003). Fewer ventilator-free days (mean difference [MD] − 12.48, 95% CI − 17.75 to − 7.22, P < 0.001) and longer ICU stays (MD 16.22, 95% CI 8.36 − 24.09, P = 0.006) were observed in patients with CMV reactivation, which remained significant after regression adjustment, and experienced multiple adverse clinical outcomes. Subgroup analysis of the primary outcome indicated that patients with pulmonary reactivation had a higher risk of mortality. Proteomic analyses revealed suppression of immune, complement, and ribosomal subunit biogenesis pathways in BALF, along with activation of immune responses in plasma in patients with CMV reactivation. Metabolomic analyses revealed significant upregulation of tryptophan metabolism in plasma and pyrimidine metabolism in BALF in the CMV reactivation group. Several biomarkers linked to host immune responses and viral replication, including CXCL5 (correlation coefficient [Corr.] 0.301, P = 0.038), DERPC (Corr. −0.314, P = 0.030) in BALF and PTX3 in blood (Corr. 0.291, P < 0.001) etc. were correlated with increased mortality. CONCLUSIONS: Patients with CMV reactivation exhibited a significantly poor clinical prognosis. Distinct host protein expression and metabolic alterations in different sample types were observed in the CMV reactivation group. These findings provide new insights into the impact of CMV reactivation in ARDS patients.
参考来源
- Ma H, Li T, Chen Y, et al. Clinical and biological features of CMV reactivation in ARDS: a prospective cohort study. Crit Care. 2026. PMID: 41495758. doi:10.1186/s13054-025-05738-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。